BioWorld-International-2008-10-22
Sygnis Pulls in $24M in Rights Offering for Stroke Drug Trial
Sygnis Pulls in $24M in Rights Offering for Stroke Drug Trial
Underlining the value of having big backers in these straitened times, Sygnis Pharma AG unveiled an 18.3 million (US$24.4 million) rights offering that already is fully backed by its two largest shareholders. (BioWorld International)

